The AMR Industry Alliance

What exactly is Antimicrobial Resistance (AMR)?

The hereditary or acquired capacity of microbes around us and within us allows them to resist the action of antibiotics or antimicrobials on them. As a result, the microbes in their presence evolve and multiply. Microorganisms that develop resistance to more than one antimicrobial treatment are sometimes called "superbugs", and the mechanism of developing such resistance is called antimicrobial resistance.

Because most antimicrobial compounds are produced from nature, antimicrobial resistance can evolve spontaneously; bacteria and fungi are known to develop defence mechanisms to withstand antimicrobial attacks and live, becoming antimicrobial-resistant. On the other hand, human activity plays a critical role in hastening this process and generating a global threat. Alarming rates of antibiotic resistance have been documented, and these rates continue to rise globally.

The Current Situation

Based on estimates across 204 countries and territories, the most comprehensive estimates of the global impact of antibiotic resistance to date reveal that AMR has become a leading cause of death globally. Specific areas of concern equip governments and healthcare stakeholders, and communities with the information they need to act quickly and develop a proportionate response.

What is the AMR Industry Alliance?

The AMR Industry Alliance was formed in 2017. With approximately 100 life sciences companies and trade associations, it represents nearly one-third of the sales volume and the majority of all novel products. Members have committed to report on activities they are undertaking in research & science, access to antibiotics and appropriate use of these, and responsible environmental manufacturing to tackle the rapid spread of antimicrobial resistance. If AMR remains unchecked, the annual death toll could climb from 700,000 each year to 10 million by 2050, and the economic impacts could be on par with those of the 2008 financial crisis. The AMR Industry Alliance ensures that signatories collectively deliver on the specific commitments made in the Industry Declaration on AMR and the Roadmap for Progress on Combating AMR and measures progress made in the fight against AMR.

Venus Remedies Limited Joins The Force

The organization has been supporting the initiatives being carried out by the AMR Industry Alliance for quite some time. On February 7th, 2022, Venus officially joined the alliance to participate in the biggest coalition of 100+ renowned global organizations that align with the AMR Industry Alliance's noble vision to develop solutions to combat the grave public health threat posed by Antimicrobial Resistance (AMR).

Welcoming Venus Remedies Limited as a new member, Melissa Mitchell, Secretariat Lead of AMR (antimicrobial resistance) Industry Alliance, said, "We are delighted to have Venus Remedies Limited join our ranks. As an organization, they lead by example and make commendable efforts to counter the threat of AMR by improving the access of AMR-relevant drugs to third-world countries, encouraging appropriate antibiotic use, and practical stewardship activities. Leading companies in the life science sector, like Venus Remedies Limited, are playing a vital role in the mitigation of AMR and continue to strengthen multi-stakeholder collaborations,"

The organization's participation in the AMR Industry Alliance adds life into the role of guaranteeing safe antibiotic manufacturing and availability as a part of the company's continued efforts to join forces with other organizations in a determined battle against AMR on a global scale.

"It is an honour to collaborate with the global life sciences industry under the aegis of the AMR Industry Alliance and devise sustainable solutions to AMR. We hope this association will amplify our existing efforts against AMR at a global level by shaping relevant AMR policies and plugging the leaks in the current antibiotic research and manufacturing landscape with a focus on access and appropriate use,"

Saransh Chaudhary
CEO | Venus Medicine Research Centre (VMRC)
President | Global Critical Care, Venus Remedies Limited

References

• https://www.unep.org/explore-topics/chemicals-waste/what-we-do/emerging-issues/antimicrobial-resistance-global-threat
• https://www.theweek.in/wire-updates/business/2022/02/07/nrg4-ch-biz-venus-remedies-amria.html
• https://www.healthdata.org/news-release/latest-estimates-global-anti-microbial-resistance-show-urgent-policy-action-needed-save
• https://health.economictimes.indiatimes.com/news/pharma/venus-remedies-joins-amr-industry-alliance/89407269